Who are Curosurf-Group1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Poractant alfa (Curosurf®), Bolus surfactant, Poractant alfa instillation, Surfactant nebulisation, Aerosolized Calfactant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/curosurf-group1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Curosurf-Group1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Curosurf-Group1 (Curosurf-Group1) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pulmonary surfactant replacement. Area: Respiratory/Neonatology.

phase 3 Pulmonary surfactant replacement Pulmonary surfactant (phospholipid and protein complex) Respiratory/Neonatology Small molecule Live · refreshed every 30 min

Target snapshot

Curosurf-Group1 (Curosurf-Group1) — Ottawa Hospital Research Institute. Curosurf is a natural pulmonary surfactant that replaces deficient surfactant in the lungs to improve gas exchange and reduce surface tension in the alveoli.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Curosurf-Group1 TARGET	Curosurf-Group1	Ottawa Hospital Research Institute	phase 3	Pulmonary surfactant replacement	Pulmonary surfactant (phospholipid and protein complex)
Poractant alfa (Curosurf®)	Poractant alfa (Curosurf®)	Chiesi Farmaceutici S.p.A.	marketed	Pulmonary surfactant replacement therapy
Bolus surfactant	Bolus surfactant	Zekai Tahir Burak Women's Health Research and Education Hospital	marketed	Pulmonary surfactant replacement therapy
Poractant alfa instillation	Poractant alfa instillation	Poznan University of Medical Sciences	marketed	Pulmonary surfactant replacement	Pulmonary surfactant (lipid and protein complex)
Surfactant nebulisation	Surfactant nebulisation	University of Zurich	phase 3	Pulmonary surfactant replacement therapy
Aerosolized Calfactant	Aerosolized Calfactant	ONY	phase 3	Pulmonary surfactant replacement	Pulmonary surfactant (lipid-protein complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pulmonary surfactant replacement class)

ONY · 1 drug in this class
Ottawa Hospital Research Institute · 1 drug in this class
Poznan University of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Curosurf-Group1 — Competitive Intelligence Brief. https://druglandscape.com/ci/curosurf-group1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab